TAZOVID
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

TAZOVID Trademark

Serial Number: 79372184 • Registration: 7525664

TAZOVID is a trademark filed by FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. on April 13, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (4 trademarks)

Building 1-7, Fuyuan Industrial Zone,

Entity Type: 99

Trademark Details

Filing Date

April 13, 2023

Registration Date

October 8, 2024

Published for Opposition

July 23, 2024

Goods & Services

Medicines for human purposes for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; Pharmaceutical preparations for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; Capsules being medicines for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; Drugs for medical purposes for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; vaccines; Ointments for pharmaceutical purposes for the treatment of skin conditions; Medicines in the form of tablets for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; biocides; Dietetic preparations adapted for medical purposes; Depuratives for the body; Medicines for veterinary purposes for the treatment of COVID-19; dental lacquer

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 4, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 18, 2025 FICS
FINAL DISPOSITION PROCESSED
Mar 18, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 8, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 8, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 8, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jul 23, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 14, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 14, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 14, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 14, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 14, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 13, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 13, 2024 TROA
REFUSAL PROCESSED BY IB
Feb 19, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 1, 2024 RFCS
REFUSAL PROCESSED BY MPU
Feb 1, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 18, 2024 RFCR
NON-FINAL ACTION WRITTEN
Jan 17, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 10, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 27, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 23, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 22, 2023 REPR